XSTO
ORX
Market cap56mUSD
Jun 02, Last price
15.60SEK
1D
7.44%
1Q
-2.38%
Jan 2017
-58.51%
IPO
-82.66%
Name
Orexo AB
Chart & Performance
Profile
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 590,000 -7.64% | 638,800 2.32% | 624,300 10.50% | |||||||
Cost of revenue | 768,700 | 761,500 | 821,900 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (178,700) | (122,700) | (197,600) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 12,400 | (12,000) | 7,200 | |||||||
Tax Rate | ||||||||||
NOPAT | (191,100) | (110,700) | (204,800) | |||||||
Net income | (203,000) 58.22% | (128,300) -27.76% | (177,600) -20.54% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 10,000 | 20,900 | 20,600 | |||||||
Long-term debt | 482,000 | 478,300 | 563,800 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 24,000 | 11,600 | 10,200 | |||||||
Net debt | 368,700 | 328,200 | 451,300 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (32,600) | (95,000) | (156,600) | |||||||
CAPEX | (4,600) | (18,500) | (23,900) | |||||||
Cash from investing activities | (5,300) | 200,800 | (234,700) | |||||||
Cash from financing activities | (15,500) | (70,100) | (21,400) | |||||||
FCF | (218,800) | (125,600) | (218,700) | |||||||
Balance | ||||||||||
Cash | 123,300 | 171,000 | 351,800 | |||||||
Long term investments | (218,700) | |||||||||
Excess cash | 93,800 | 139,060 | 101,885 | |||||||
Stockholders' equity | (1,757,000) | (1,622,000) | ||||||||
Invested Capital | 373,700 | 2,301,300 | 2,361,400 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 34,465 | 34,413 | 34,352 | |||||||
Price | 17.50 13.20% | 15.46 -18.03% | 18.86 -45.33% | |||||||
Market cap | 603,141 13.37% | 532,031 -17.88% | 647,874 -45.28% | |||||||
EV | 971,841 | 860,231 | 1,099,174 | |||||||
EBITDA | 10,500 | (45,600) | (128,900) | |||||||
EV/EBITDA | 92.56 | |||||||||
Interest | 41,200 | 27,800 | ||||||||
Interest/NOPBT |